Progress in molecular biology of myelodysplastic syndromes with trisomy 8

VernacularTitle: 伴8号染色体三体的骨髓增生异常综合征分子生物学研究进展
Author: Linlin ZHENG ¹ ; Yanjuan LIN
Author Information

1. Department of Hematology, Fujian Institute of Hematology, Key Laboratory of Hematology of Fujian Province, Fujian Medical University Union Hospital, Fuzhou 350001, China
Publication Type:Review
Keywords: Myelodysplastic syndromes; Trisomy 8; Molecular biology
From: Journal of Leukemia & Lymphoma 2018;27(8):497-501
CountryChina
Language:Chinese
Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid clonal disease deriving from hematopoietic stem cells, which is mainly characterized with bone marrow failure and abnormal cloning. Trisomy 8 is the most common chromosomal abnormality in MDS. Current studies have found that gene amplification, gene mutation, abnormal expression of microRNA, high expression of Wilms tumor 1 protein, Survivin and miR-661 are related to trisomy 8, which play roles in the abnormality of clone and apoptosis of MDS. This article summarizes the molecular biology transformation and clinical treatment progress of MDS with trisomy 8.